Movers Lab Fund I. Lp Prime Sells 405,217 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) Stock

Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 405,217 shares of the firm’s stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $3.35, for a total value of $1,357,476.95. Following the completion of the transaction, the insider now directly owns 8,764,372 shares in the company, valued at $29,360,646.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Vaxxinity Stock Performance

Shares of NASDAQ:VAXX traded up $0.25 during trading hours on Wednesday, hitting $3.14. The stock had a trading volume of 452,755 shares, compared to its average volume of 594,560. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.33 and a current ratio of 3.33. The stock’s fifty day simple moving average is $1.87 and its 200 day simple moving average is $1.91. The firm has a market capitalization of $395.82 million, a price-to-earnings ratio of -2.49 and a beta of 0.55. Vaxxinity, Inc. has a 1-year low of $1.24 and a 1-year high of $8.35.

Vaxxinity (NASDAQ:VAXX – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Sell-side analysts anticipate that Vaxxinity, Inc. will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxxinity

Several hedge funds have recently bought and sold shares of VAXX. Hollencrest Capital Management acquired a new position in Vaxxinity during the 2nd quarter worth $31,000. Clarius Group LLC acquired a new position in shares of Vaxxinity during the 2nd quarter worth about $31,000. Truist Financial Corp bought a new stake in Vaxxinity during the 2nd quarter valued at approximately $33,000. Bank of America Corp DE grew its holdings in Vaxxinity by 7,829.0% in the 1st quarter. Bank of America Corp DE now owns 15,858 shares of the company’s stock valued at $68,000 after buying an additional 15,658 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Vaxxinity in the 2nd quarter worth approximately $335,000. 20.84% of the stock is owned by institutional investors and hedge funds.

Vaxxinity Company Profile

(Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.